Showing 4941-4950 of 5355 results for "".
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Foamix Pharmaceuticals Will Host Key Opinion Leader Meeting and Webcast on November 4th in New York Cityhttps://practicaldermatology.com/news/20141029-foamix_pharmaceuticals_will_host_key_opinionleader_meeting_and_webcast_on_november_4th_in_new_york_city/2459077/Foamix Pharmaceuticals Ltd. will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City. The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kes
- Nerium International Announces Creation of Scientific Advisory Boardhttps://practicaldermatology.com/news/20141027-nerium_international_announces_creation_of_scientific_advisory_board/2459078/Nerium International established a Scientific Advisory Board, comprised of the following scientists and dermatologists: Dr. Adam Friedman, Dr. Neal Bhatia, Dr. Mira Stotland, Marie Bertrand, Dr. Debra J. Wattenberg, and Dr. Karthik Krishnamurthy. The mission of the
- Restoration Robotics has Harvested the 10 Millionth Hair with the Artas® Robotic Systemhttps://practicaldermatology.com/news/20141024-restoration_robotics_has_harvested_the_10_millionth_hair_with_the_artas_robotic_system/2459080/Dr. Eduardo López Bran, a member of the International Society of Hair Restoration Society said, "We are excited to have harvested the 10 millionth hair. “It is important that my practice continues to offer the most advanced hair restoration procedures to our patients. The ARTAS Robotic Sys
- Novel Molecule Promising in Hyperhidrosis Pilot Studyhttps://practicaldermatology.com/news/20141016-novel_molecule_promising_in_hyperhidrosis_pilot_study/2459082/The outcome of a pilot study of BBI-4000, new compound for the topical treatment of primary axillary hyperhidrosis, support the potential for BBI-4000 to become a safe and effective treatment option for people suffering from excessive sweating. BBI-4000 is a new molecular entity from Brickell Biotec
- NYAM Academic Research Awards in Dermatology Program Accepting Applicationshttps://practicaldermatology.com/news/20141016-nyam_academic_research_awards_in_dermatology_program_accepting_applications/2459083/The application period is now open for the NYAM Academic Research Awards in dermatology program. Deadline for applications is December 15, 2014. The NYAM Academic Research Awards Program provides funding for residents and early-career dermatologists performing basic science or clinical research re